Dentsply Sirona (XRAY) Q4 2025 earnings review
Dividend Slashed and 2026 Guidance Resets Expectations
Dentsply Sirona reported Q4 revenue growth of 6.2%, but this headline figure masks deeper structural issues, as it heavily benefited from lapping a disastrous Q4 2024 (which included the Byte wind-down). Management is taking drastic actions: eliminating the dividend entirely, initiating a new $120M restructuring program, and taking another $144M impairment charge. FY26 guidance paints a sobering picture, with revenue expected to reverse back into contraction ($3.5-$3.6B) and Adjusted EPS decelerating to $1.40-$1.50. The core business continues to suffer from U.S. market weakness and tariff pressures, forcing a total capital allocation reset.
🐂 Bull Case
The new restructuring plan aims to deliver $120M in annualized savings. Eliminating the $128M annual dividend provides immediate liquidity to pay down debt and repurchase shares at what management believes are undervalued levels.
The company established new agreements with major distributors Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec, potentially stabilizing the struggling U.S. equipment channel.
🐻 Bear Case
FY26 Adjusted EPS guidance of $1.40-$1.50 implies a 6% to 12% decline versus FY25. The core turnaround is not dropping to the bottom line, offset by tariffs, reinvestment needs, and weak volumes.
Free Cash Flow collapsed 63% in FY25 to just $104M. Eliminating the dividend appears to be as much a necessity for balance sheet protection as it is a strategic capital allocation choice.
⚖️ Verdict: 🔴
Bearish. While management's 'Return-to-Growth' initiatives and restructuring are necessary medicine, the FY26 guidance indicates that the pain will continue. The complete elimination of the dividend reflects severe cash generation constraints.
Key Themes
Impairments Contradict the 'Turnaround' Narrative
Management stated they delivered results 'in line with expectations,' yet recorded another $144M non-cash impairment in Q4 related to Orthodontic and Implant Solutions (OIS) and Connected Technology Solutions (CTS). For the full year, impairments totaled a staggering $650M. This data point proves that lower-than-expected equipment and implant volumes are causing structural, permanent value destruction rather than just temporary macro softness.
Restructuring to Fund Innovation
The Board approved a massive restructuring program expected to cost $55-$65M but yield ~$120M in annualized savings. The critical driver here is that savings will be redirected into the 'Return-to-Growth' plan, funding accelerated clinical education, sales team expansion, and connected dentistry investments like DS Core.
Dividend Elimination Highlights Liquidity Preservation
Dentsply suspended its quarterly cash dividend, which consumed $128M in FY25. While framed as a 'capital deployment strategy' to reduce debt and buy back shares, this move coincides with a 63% YoY drop in FY25 Free Cash Flow. The underlying cash engine of the business is stalling, making the dividend unsustainable.
Tariff and Macro Headwinds Persist
The 2026 outlook explicitly bakes in management's current expectations regarding tariffs and trade policies. In prior quarters, management noted a $50M+ gross exposure to tariffs. Gross margins in Q4 deteriorated to 46.2% (GAAP) from 49.2% a year ago, reflecting these ongoing supply chain and geographic pressures.
Distribution Network Expansion
A key piece of the U.S. turnaround is commercial execution. Dentsply successfully established new agreements with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec. This multi-channel approach is crucial for revitalizing the lagging Connected Technology Solutions (CTS) segment, which relies heavily on equipment distribution.
Portfolio Diversification: Surity Launch
The company launched the Surity™ Female External Catheter, marking its entry into a new market category in the U.S. While a small piece of the overall pie, this leverages the fast-growing Wellspect Healthcare segment, which saw Q4 constant currency sales rise 1.9% and FY25 CC sales rise 3.9%.
Other KPIs
Reversing. After expanding margins to 21.1% in Q2 and 18.4% in Q3, Q4 Adjusted EBITDA margin compressed sharply back to 14.1%, essentially flat with Q4 2024's 14.2%. This indicates severe negative operating leverage and rising Q4 expenses.
Down 3.0% as reported and down 4.3% in constant currency. The U.S. market was the primary drag, declining 12.3% for the full year, severely impacting Orthodontic and Implant Solutions (down 24.6% in the U.S.).
Accelerating. Long-term debt increased from $1,586 million at the end of 2024 to $2,015 million at the end of 2025. Coupled with the Free Cash Flow decline, this balance sheet deterioration clarifies the urgent need to eliminate the dividend.
Guidance
Decelerating/Reversing. Compared to FY25 actuals of $3.68 billion, this implies a year-over-year contraction of roughly 2% to 5%. This signals that the core dental turnaround and new dealer agreements will not be enough to offset macro headwinds or product sunsets in 2026.
Decelerating. At the midpoint ($1.45), this implies a 9.4% drop from FY25's $1.60, which was already down from FY24's $1.67. This validates that the $120M in restructuring savings will be heavily reinvested or absorbed by lower volumes and tariff costs, offering no net bottom-line growth.
Key Questions
Restructuring Net Benefit
Of the $120M in anticipated annualized cost savings, how much is expected to drop to the bottom line in 2026 versus being fully absorbed by tariff costs and 'Return-to-Growth' reinvestments?
Dividend Elimination and Debt Targets
With the quarterly dividend completely eliminated, what is your targeted Net Debt to EBITDA ratio, and at what leverage threshold will you begin aggressive share repurchases?
Implied 2026 Revenue Contraction
Your 2026 revenue guide of $3.5B-$3.6B implies negative growth against 2025. Is this primarily driven by expected U.S. market share losses, ongoing elective procedure softness, or specific product portfolio pruning?